



Clinical trial results:

Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with end-of-dose motor fluctuations and associated pain.

Summary

EudraCT number	2020-001175-32
Trial protocol	GB PT IT CZ PL
Global end of trial date	16 February 2024

Results information

Result version number	v1 (current)
This version publication date	30 May 2025
First version publication date	30 May 2025
Summary attachment (see zip file)	BIA-91067-404_CTR Synopsis (BIA-91067-404_CTR Synopsis.pdf)

Trial information

Trial identification

Sponsor protocol code	BIA-91067-404
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04986982
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bial - Portela & Ca, S.A.
Sponsor organisation address	À Av. da Siderurgia Nacional, Trofa, Portugal, 4745-457
Public contact	Ruben Arnelas, Bial - Portela & Ca, S.A., +351 229866100, clinical.trials@bial.com
Scientific contact	Responsible of Clinical Development, Bial - Portela & Ca, S.A., +351 229866100, clinical.trials@bial.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 May 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 February 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to investigate the efficacy of opicapone 50 mg when administered with the existing treatment of L-DOPA plus a DDCI, in PD patients with end-of-dose motor fluctuations and associated pain.

Protection of trial subjects:

This study was performed in neurological centres and conducted in compliance with the study protocol, by the study personnel, who were qualified by education, training, and experienced in their roles. The patients were closely monitored during the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 February 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 28
Country: Number of subjects enrolled	Czechia: 26
Country: Number of subjects enrolled	Portugal: 20
Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	United Kingdom: 19
Country: Number of subjects enrolled	Germany: 8
Country: Number of subjects enrolled	Italy: 10
Worldwide total number of subjects	127
EEA total number of subjects	108

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	52
From 65 to 84 years	74
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The recruitment was terminated before reaching the estimated number of randomised patients. However, this had no impact on the analysis of data since the drop-out rate was less than 15% and thus the planned number of evaluable patients was reached. A total of 19 patients prematurely terminated the study.

Pre-assignment

Screening details:

A total of 144 patients were enrolled at 44 active sites in Europe. Of these, 127 patients were randomised and received at least 1 dose of IP. A total of 122 patients met the criteria for the Full Analysis Set including 59 opicapone 50 mg patients and 63 placebo patients.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Group A - Opicapone

Arm description:

Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Arm type	Experimental
Investigational medicinal product name	Opicapone
Investigational medicinal product code	BIA 9-1067
Other name	Ongentys
Pharmaceutical forms	Oral suspension, Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI.

Arm title	Group B - Placebo
------------------	-------------------

Arm description:

Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	Placebo
Pharmaceutical forms	Capsule, hard, Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Number of subjects in period 1	Group A - Opicapone	Group B - Placebo
Started	64	63
Completed	53	55
Not completed	11	8
Consent withdrawn by subject	3	1
Adverse event, non-fatal	4	4
Ineligibility	3	-
Sponsor's discretion	1	-
Lost to follow-up	-	1
Lack of efficacy	-	2

Baseline characteristics

Reporting groups

Reporting group title	Group A - Opicapone
-----------------------	---------------------

Reporting group description:

Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Reporting group title	Group B - Placebo
-----------------------	-------------------

Reporting group description:

Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Reporting group values	Group A - Opicapone	Group B - Placebo	Total
Number of subjects	64	63	127
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	23	29	52
From 65-84 years	40	34	74
85 years and over	1	0	1
Age continuous			
Units: years			
median	67.0	65	-
standard deviation	± 9.14	± 9.39	-
Gender categorical			
Units: Subjects			
Female	31	31	62
Male	33	32	65
Race			
Units: Subjects			
White	64	62	126
Black or African American	0	0	0
Asian	0	0	0
American Indian or Alaska Native	0	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Unknown	0	0	0

End points

End points reporting groups

Reporting group title	Group A - Opicapone
Reporting group description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI	
Reporting group title	Group B - Placebo
Reporting group description: Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI	

Primary: Change From Baseline in Domain 3 (Fluctuation-related Pain) of KING's PARKINSON's DISEASE PAIN SCALE (KPPS)

End point title	Change From Baseline in Domain 3 (Fluctuation-related Pain) of KING's PARKINSON's DISEASE PAIN SCALE (KPPS)
End point description: The KING's PARKINSON's DISEASE PAIN SCALE (KPPS) evaluates the burden (global and bedside) and characterises various phenotypes of pain in Parkinson's disease. The investigator will complete the questionnaire by interviewing the patient about seven domains and answering to 14 items. The questionnaire will be fill out on Visit 1, Visit 2b/Baseline, Visit 4, Visit 5 and Visit 6/EDV Domain 3 assesses fluctuation-related pain (score range: 0 - 36). Higher score values indicate higher levels of pain.	
End point type	Primary
End point timeframe: The questionnaire will be fill out on Visit 1 (Day -7 \pm 2), Visit 2b/Baseline (Day 1), Visit 4 (Day 29 (\pm 2)), Visit 5 (Day 85 (\pm 4)) and Visit 6/Early Discontinuation Visit (EDV) (Day 169 (\pm 4)) - Up to 24 weeks	

End point values	Group A - Opicapone	Group B - Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	59	63		
Units: Score on a scale				
arithmetic mean (standard deviation)				
Visit 1 (Day -7 \pm 2)	17.2 (\pm 5.72)	16.7 (\pm 5.18)		
Visit 2b (Day 1)	17.1 (\pm 5.58)	16.9 (\pm 5.20)		
Baseline (Day 1)	17.1 (\pm 5.58)	16.9 (\pm 5.20)		
Visit 4 (Day 29 (\pm 2)) - Observed Value	10.5 (\pm 7.92)	11.0 (\pm 7.51)		
Visit 4 (Day 29 (\pm 2)) - Change from Baseline	-6.6 (\pm 7.28)	-5.9 (\pm 6.02)		
Visit 5 (Day 85 (\pm 4)) - Observed Value	8.3 (\pm 7.27)	9.3 (\pm 5.73)		
Visit 5 (Day 85 (\pm 4)) - Change from Baseline	-8.7 (\pm 6.68)	-7.6 (\pm 6.13)		
Visit 6 (Day 169 (\pm 4)) - Observed Value	8.4 (\pm 6.93)	7.5 (\pm 6.48)		
Visit 6 (Day 169 (\pm 4)) - Change from Baseline	-8.8 (\pm 6.85)	-9.3 (\pm 6.24)		

Statistical analyses

Statistical analysis title	Change from baseline in Domain 3 of KPPS
Statistical analysis description:	
The King's Parkinson's Disease Pain Scale (KPPS) evaluates the burden (global and bedside) and characterises various phenotypes of pain in PD. Its seven domains include 14 items, each item scored by severity (0-3) multiplied by frequency (0-4), resulting in subscores of 0 to 12. The total possible KPPS score (0 to 168) represents the symptomatic burden by pain. The questionnaire will be fill out on Visit 1, Visit 2b, Visit 4, Visit 5 and Visit 6/EDV.	
Comparison groups	Group B - Placebo v Group A - Opicapone
Number of subjects included in analysis	122
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.794
Method	Mixed models analysis
Confidence interval	
sides	2-sided
lower limit	-1.96
upper limit	2.55
Variability estimate	Standard deviation

Adverse events

Adverse events information

Timeframe for reporting adverse events:

The period of monitored/assessed for the collection of AEs were through study completion, about 3 years.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Opicapone 50 mg
-----------------------	-----------------

Reporting group description:

Opicapone 50 mg: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo: Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Serious adverse events	Opicapone 50 mg	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 64 (6.25%)	2 / 63 (3.17%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events		0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Non-small cell lung cancer			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			

subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Faecaloma			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Opicapone 50 mg	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 64 (62.50%)	36 / 63 (57.14%)	
Vascular disorders			
Hypertension			

subjects affected / exposed	2 / 64 (3.13%)	1 / 63 (1.59%)	
occurrences (all)	2	1	
Deep vein thrombosis			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Hypotension			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Orthostatic hypotension			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Varicose vein			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Pain			
subjects affected / exposed	5 / 64 (7.81%)	3 / 63 (4.76%)	
occurrences (all)	6	3	
Fatigue			
subjects affected / exposed	2 / 64 (3.13%)	2 / 63 (3.17%)	
occurrences (all)	2	2	
Oedema peripheral			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Application site irritation			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Asthenia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Malaise			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Reproductive system and breast disorders			

Benign prostatic hyperplasia subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 63 (1.59%) 1	
Pruritus genital subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Nasal congestion subjects affected / exposed occurrences (all)	2 / 64 (3.13%) 2	0 / 63 (0.00%) 0	
Atelectasis subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 63 (1.59%) 1	
Dysphonia subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 63 (1.59%) 1	
Epistaxis subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Psychiatric disorders			

Anxiety		
subjects affected / exposed	6 / 64 (9.38%)	2 / 63 (3.17%)
occurrences (all)	6	3
Insomnia		
subjects affected / exposed	3 / 64 (4.69%)	3 / 63 (4.76%)
occurrences (all)	3	3
Depression		
subjects affected / exposed	3 / 64 (4.69%)	1 / 63 (1.59%)
occurrences (all)	3	1
Hallucination, visual		
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)
occurrences (all)	1	1
Abnormal dreams		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Bruxism		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Delirium		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Delusion		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Depressed mood		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Hallucinations, mixed		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Illusion		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Impulse-control disorder		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0

Irritability			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Mood altered			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Nightmare			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Obsessive-compulsive disorder			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Sleep disorder			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Terminal insomnia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Investigations			
Blood pressure decreased			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Body temperature increased			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Weight decreased			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	2 / 64 (3.13%)	3 / 63 (4.76%)	
occurrences (all)	7	3	
Skin abrasion			

subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Skin laceration			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Arthropod sting			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Chest injury			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Wrist fracture			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Arteriosclerosis coronary artery			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Atrial fibrillation			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Cardiomegaly			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dyskinesia			
subjects affected / exposed	3 / 64 (4.69%)	4 / 63 (6.35%)	
occurrences (all)	3	4	
Headache			
subjects affected / exposed	3 / 64 (4.69%)	3 / 63 (4.76%)	
occurrences (all)	4	3	
Parkinson's disease			

subjects affected / exposed	3 / 64 (4.69%)	3 / 63 (4.76%)
occurrences (all)	3	3
Dizziness		
subjects affected / exposed	1 / 64 (1.56%)	3 / 63 (4.76%)
occurrences (all)	1	4
On and off phenomenon		
subjects affected / exposed	2 / 64 (3.13%)	2 / 63 (3.17%)
occurrences (all)	2	2
Sciatica		
subjects affected / exposed	2 / 64 (3.13%)	0 / 63 (0.00%)
occurrences (all)	2	0
Altered state of consciousness		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Balance disorder		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Bradykinesia		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Dystonia		
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)
occurrences (all)	0	1
Freezing phenomenon		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Hemiparesis		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Hypoaesthesia		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Memory impairment		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Poor quality sleep		

subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Restless legs syndrome			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Somnolence			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Taste disorder			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Tension headache			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Tremor			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 64 (3.13%)	1 / 63 (1.59%)	
occurrences (all)	2	2	
Eye disorders			
Diplopia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Visual acuity reduced			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	7 / 64 (10.94%)	5 / 63 (7.94%)	
occurrences (all)	8	5	
Constipation			

subjects affected / exposed	5 / 64 (7.81%)	1 / 63 (1.59%)
occurrences (all)	5	1
Dyspepsia		
subjects affected / exposed	2 / 64 (3.13%)	1 / 63 (1.59%)
occurrences (all)	2	1
Dry mouth		
subjects affected / exposed	2 / 64 (3.13%)	0 / 63 (0.00%)
occurrences (all)	2	0
Vomiting		
subjects affected / exposed	0 / 64 (0.00%)	2 / 63 (3.17%)
occurrences (all)	0	2
Abdominal pain		
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)
occurrences (all)	0	1
Crohn's disease		
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)
occurrences (all)	0	1
Diarrhoea		
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Gastrointestinal disorder		
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)
occurrences (all)	0	1
Oral discomfort		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Salivary hypersecretion		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	1	0
Toothache		
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)
occurrences (all)	3	0
Umbilical hernia		

subjects affected / exposed occurrences (all)	1 / 64 (1.56%) 1	0 / 63 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Skin lesion			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Nocturia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Renal cyst			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Ureterolithiasis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Urinary incontinence			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Musculoskeletal stiffness			
subjects affected / exposed	2 / 64 (3.13%)	2 / 63 (3.17%)	
occurrences (all)	2	2	
Arthralgia			
subjects affected / exposed	1 / 64 (1.56%)	2 / 63 (3.17%)	
occurrences (all)	1	2	

Back pain			
subjects affected / exposed	0 / 64 (0.00%)	3 / 63 (4.76%)	
occurrences (all)	0	3	
Pain in extremity			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Limb discomfort			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Mobility decreased			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Muscle spasms			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Musculoskeletal pain			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Rheumatoid arthritis			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
COVID-19			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Influenza			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Upper respiratory tract infection			
subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Urinary tract infection			

subjects affected / exposed	1 / 64 (1.56%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Nasopharyngitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Oral candidiasis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Pharyngitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Tonsillitis bacterial			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Tooth abscess			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Viral infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 64 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 64 (3.13%)	1 / 63 (1.59%)	
occurrences (all)	2	1	
Folate deficiency			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Vitamin B12 deficiency			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Vitamin D deficiency			
subjects affected / exposed	1 / 64 (1.56%)	0 / 63 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported